Lexicon Pharmaceuticals (LXRX) Gross Margin (2016 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Gross Margin for 10 consecutive years, with 99.49% the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Margin rose 187.0% year-over-year to 99.49%; the TTM figure through Mar 2026 stood at 99.49% (up 146.0% YoY), while the FY2025 annual figure was 99.45%, up 143.0% from the prior year.
• Gross Margin climbed to 99.49% in Q1 2026 per LXRX's latest filing, from 96.34% in the prior quarter.
• Across five years, Gross Margin topped out at 100.0% in Q2 2022 and bottomed at 89.92% in Q2 2024.
• Historically, Gross Margin has averaged 96.83% across 5 years, with a median of 97.25% in 2023.
• Annual changes were most pronounced in 2024 — Gross Margin tumbled 733 bps — and 2025, when it soared 996 bps.
• Lexicon Pharmaceuticals' Gross Margin stood at 100.0% in 2022, then decreased by 9 bps to 90.86% in 2023, then climbed by 9 bps to 98.69% in 2024, then retreated by 2 bps to 96.34% in 2025, then increased by 3 bps to 99.49% in 2026.
• Business Quant data shows LXRX's Gross Margin at 99.49% in Q1 2026, 96.34% in Q4 2025, and 99.93% in Q3 2025.